Tyra Biosciences (TYRA) Operating Leases (2021 - 2026)

Tyra Biosciences has reported Operating Leases for 6 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 8.55% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 8.55% YoY), and the FY2025 full-year result was $5.3 million, down 8.12% from the prior year.
• Operating Leases for Q1 2026 stood at $5.2 million, down from $5.3 million in the prior quarter.
• The five-year high for Operating Leases was $6.2 million in Q4 2023, with the low at $2.4 million in Q1 2023.
• Historically, Operating Leases has averaged $5.0 million across 5 years, with a median of $5.6 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases soared 153.01% — and 2023, when it tumbled 55.56%.
• Tyra Biosciences' Operating Leases stood at $2.5 million in 2022, then surged by 150.44% to $6.2 million in 2023, then dropped by 6.53% to $5.8 million in 2024, then fell by 8.12% to $5.3 million in 2025, then fell by 2.42% to $5.2 million in 2026.
• The last three Operating Leases figures came in at $5.2 million (Q1 2026), $5.3 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.